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Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in 
Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein 
occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated 
in a biodegradable copolymer to release the active ingredient within the vitreous chamber for 
up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between 
injections with a good safety profile. Various other ocular pathologies with inflammatory etio-
pathogeneses associated with macular edema have been treated by DEX implant, including 
neovascular age-related macular degeneration, Irvine–Gass syndrome, vasoproliferative retinal 
tumors, retinal telangiectasia, Coats’ disease, radiation maculopathy, retinitis pigmentosa, 
and macular edema secondary to scleral buckling and pars plana vitrectomy. We undertook a 
review to provide a comprehensive collection of all of the diseases that benefit from the use 
of the sustained-release DEX implant, alone or in combination with concomitant therapies. 
A MEDLINE search revealed lack of randomized controlled trials related to these indications. 
Therefore we included and analyzed all available studies (retrospective and prospective, com-
parative and non-comparative, randomized and nonrandomized, single center and multicenter, 
and case report). There are reports in the literature of the use of DEX implant across a range of 
macular edema-related pathologies, with their clinical experience supporting the use of DEX 
implant on a case-by-case basis with the aim of improving patient outcomes in many macular 
pathologies. As many of the reported macular pathologies are difficult to treat, a new treat-
ment option that has a beneficial influence on the clinical course of the disease may be useful 
in clinical practice.
Keywords: macular edema, dexamethasone, intravitreal, implant, corticosteroids
Introduction
The sustained-release intravitreal (IV) 0.7 mg dexamethasone (DEX) implant 
(Ozurdex®, Allergan Pharmaceuticals, Irvine, CA, USA) is approved in Europe for 
the treatment of macular edema related to the following diseases: diabetic retin-
opathy, branch retinal vein occlusion or central retinal vein occlusion, and non- 
infectious uveitis.1
DEX is one of the 3 most commonly used intraocular corticosteroids together with 
triamcinolone acetonide (TA) and fluocinolone acetonide. However, compared with 
these, DEX differs in its pharmacokinetics and pharmacodynamics properties due 
to certain biological effectiveness: different glucocorticoid receptor binding affinity 
(DEX . fluocinolone . triamcinolone) and different anti-inflammatory activities 
(DEX = fluocinolone and is 5 times more active than triamcinolone).1,2 The advantage 
of a DEX implant, containing micronized, preservative-free DEX 0.7 mg in a bio-
degradable copolymer of polylactic-co-glycolic acid (which eventually breaks down 
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into carbon dioxide and water), is the release of the active 
ingredient within the vitreous chamber for up to 6 months 
after an IV injection. All these aforementioned features 
allow reduction in the frequency of injections with benefit 
in terms of hospital and patient resource saving, including 
diminished complications related to injection procedure (eg, 
retinal detachment, endophthalmitis, lens iatrogenic injury, 
etc). However, in real life it has been shown that a shorter-
interval re-treatment is required because of the loss of the 
drug’s effectiveness before 6 months, with a reported range 
varying from 4 to 5.9 months.3,4 Another relevant pharma-
cological aspect, as demonstrated by experimental studies, 
is the reduction of IV drugs half-life in vitrectomized eyes 
compared with non-vitrectomized ones, making their use 
ineffective.5 On the contrary, DEX implant has the advantage 
of maintaining the same half-life and, therefore, the same 
pharmacological properties in both vitrectomized and non-
vitrectomized eyes.6–8
Regarding complications related to the use of DEX 
implant, pivotal studies and real-life studies have confirmed 
a good safety profile with only a few complications: cataract 
progression in the range from 29.8%9 to 67.9%,10 closely 
related to the number of implants received, and an increase of 
intraocular pressure (IOP) .10 mmHg from baseline reported 
in a range of 15.4%9 and 27.7%10 of cases. There are several 
reviews collecting literature data about the approved use of 
sustained-release DEX implants. However, there are various 
ocular pathologies with inflammatory etiopathogeneses 
associated with macular edema, such as: neovascular age-
related macular degeneration (nAMD); Irvine–Gass syndrome 
(IGS); vasoproliferative retinal tumors (VPRTs); retinal 
telangiectasia and Coats’ disease; radiation maculopathy; 
retinitis pigmentosa; macular edema secondary to scleral 
buckling and pars plana vitrectomy (PPV), all of which have 
been treated by DEX implant.
The aim of this review was to provide a systematic 
collection of all of the diseases that benefit from the use of 
the sustained-release DEX implant alone or in combination 
with concomitant therapies in order to provide a valuable 
therapy option for these diseases in clinical practice.
Methods
MEDLINE databases for the period 2009 to September 
2016 were searched by using the medical subject heading 
“Dexamethasone intravitreal implant/Ozurdex” and the 
keywords “macular edema, age-related macular degenera-
tion, Irvine–Gass, pseudophakic cystoid macular edema, 
post-operative macular edema, PPV, scleral buckling, 
retinitis pigmentosa, prostaglandin, radiation macular 
edema, telangiectasia.” Studies were limited to the English 
language. Because randomized controlled trials on these 
topics were lacking, all studies (retrospective and prospec-
tive, comparative and non-comparative, randomized and 
nonrandomized, single center and multicenter, and case 
reports) were analyzed. Aims, and anatomical and func-
tional outcomes, and complications after DEX implant 
were analyzed.
nAMD
Approved first-line therapy for nAMD is based on the use of 
anti-vascular endothelial grow factor (VEGF) IV injections 
such as pegaptanib, ranibizumab, and aflibercept. However, 
there are patients who have a non-complete response to 
anti-VEGF injections as well as patients who, after an optimal 
functional and anatomical response, develop tachyphylaxis.11 
The explanation for this incomplete response lies in the 
multifactorial pathogenesis of AMD, which involves VEGF, 
inflammation, and oxidative stress, as seen in histological 
studies performed on neovascular membranes after their 
surgical excision. Neovascular membrane growth in the sub-
retinal space is stimulated by activated macrophages (and 
other inflammatory cells secreting cytokines) and enzymes 
that can damage the Bruch’s membrane.12 Therefore, inflam-
mation is another potential target of nAMD treatment that 
could be counteracted by the use of corticosteroids.
Combination therapy consisting of anti-VEGF therapy 
and a corticosteroid relies on the use of drugs with different 
mechanisms of action, and could allow the reduction of 
anti-VEGF IV injection frequency and therefore, improve 
long-term efficacy and safety while reducing scarring 
results.13–16 Using combination therapies to treat nAMD dates 
back to photodynamic therapy (PDT), when it was associ-
ated with the IV TA injection.17,18 However, side effects 
due to IV TA, such as cataract progression and increased 
IOP, sometimes resistant to medical therapy, halted these 
procedures despite anatomical and functional benefits.19 
Cataract surgery has been reported in around 45.2% of eyes 
that underwent triamcinolone injection,19 and ocular hyper-
tension (IOP .21 mmHg) in around 44.6% of eyes, with 
IOP-lowering surgery required in 0.3% of eyes.20
The LuceDex study21 was the first study using the IV 
DEX injections (500 mg in 0.05 mL), followed by IV ranibi-
zumab (4 monthly injections of 0.5 mg in 0.05 mL) that was 
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DeX implant for the treatment of macular edema
37 patients). After 4 consecutive months, in both groups, 
ranibizumab pro re nata treatment was administered if 
signs of lesion activity were present. The results of this study 
showed a clear benefit for combination therapy, with reduc-
tion in the dimension of the choroidal neovascular membrane, 
detected by fluorescein angiography, improvement in visual 
acuity, and reduced treatment frequency. Central macular 
thickness (CMT) and volume reductions were also observed, 
although these changes were not statistically significant.
After the approval of the DEX implant, several authors 
evaluated its efficacy in nAMD22–25 (Table 1). Compared 
with ranibizumab monotherapy, studies showed no long-term 
improvement of best corrected visual acuity (BCVA) and 
reduction of CMT;22–25 however, DEX implant in some cases 
allowed a reduced number of anti-VEGF injections.23,24
One study24 reported an incidence of cataract surgery 
of 9% in ranibizumab-treated eyes and 33% in eyes receiv-
ing 2 DEX implants. The incidence of ocular hypertension 
ranged from 15% to 42%,22–25 all treated with topical hypo-
tonizing therapy.
IGS
The most likely physiopathological hypothesis for IGS is 
an inflammatory response instigated by the inflammatory 
mediators released during and after surgical procedures, caus-
ing alterations to the blood–retinal barrier. Many risk factors 
have been identified, such as posterior capsule rupture and 
vitreous loss, as well as the use of iris retractors, the presence 
of an epiretinal membrane, a vein occlusion, a history of 
uveitis or diabetes and the use of prostaglandin eye drops.26
First-line treatment for IGS involves the use of differ-
ent therapies: topical nonsteroidal anti-inflammatory drugs 
(NSAIDs), oral acetazolamide, and topical corticosteroids. 
In patients resistant to such treatments, the following off-
label treatment options have been tried:26–32
•	 IV anti-VEGF 
•	 Subcutaneous interferon α2a injections
•	 IV infliximab (anti-tumor necrosis factor-α)
•	 Intra-, retro-, and peribulbar corticosteroids
•	 PPV
Several authors have evaluated the efficacy of DEX 
implant for chronic IGS33–45 (Table 2).
Most of the studies had a 6-month follow-up; they 
showed a significant improvement in BCVA and a significant 
reduction in CMT with 1 DEX implant. Two prospective 
studies38,43 of DEX compared with IVTA showed similar 
functional effects and anatomical effects: one found a lower 
incidence of ocular hypertension in the DEX group (at 
6 months 0% vs 20%, P=0.044).
A retrospective long-term study44 that included 58 cases 
of IGS in a total of 100 eyes found that efficacy was main-
tained at 24 months, after a mean number of 1.77 DEX 
implants in the first year and 1.70 in the second year. At 
24 months, an IOP .25 mmHg was found in 6.2% of the 
patients, all treated with hypotensive eye drops and not 
requiring filtering surgery.44
VPRTs
Several approaches have been used to treat VPRTs, including 
cryotherapy, laser photocoagulation, PDT, IV anti-VEGF, 
plaque brachytherapy, and PPV.45–47
VPRTs treated by DEX and PDT were reported in 
3 cases48 (Table 3). Total involution of the tumor was reported 
within 2 months and regression of exudates continued for 
several months, leaving fibrotic scar tissue in the inferior 
half of the retina.48
Retinal telangiectasia and Coats’ 
disease
Retinal telangiectasia
Yannuzzi et al49 have recently classified different forms 
of idiopathic macular telangiectasia: aneurismal telangi-
ectasia, idiopathic perifoveal telangiectasia, and occlusive 
telangiectasia. Although several approaches have been 
suggested for the treatment of idiopathic macular telangi-
ectasia (including laser photocoagulation,50 PDT,51 IV anti-
VEGF,52 PPV53), no treatment has yet been shown to provide 
a consistent effect on visual acuity. Also, corticosteroids have 
been used to treat these vascular pathologies due to their 
biological effect54 and DEX implant can be assumed to be an 
useful therapeutic device,55,56 which can also be administered 
in pediatric patients57 (Table 4).
In these cases, with a longer follow-up, multiple DEX 
implants were performed, at each time successfully (leading 
to BCVA improvement and CMT reduction).56–58
Coats’ disease
In Coats’ disease, ablative therapy by laser photocoagula-
tion and cryotherapy is the gold standard of treatment57 with 
photocoagulation preferred over cryotherapy in cases with 
little or no subretinal fluid.57 IV therapies such as anti-VEGF 
and steroids could be used to improve anatomic and visual 
outcomes,58,59 in particular, in combination with ablative 
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have been used to reduce intraocular inflammation, tighten 
capillary walls, and suppress cell proliferation, also having 
anti-VEGF properties,58 (Table 5).
In one case, DEX implant led to a resolution of the exu-
dative retinal detachment allowing laser photocoagulation 
of telangiectatic vessels.63 In other cases, final BCVA was 
influenced by subfoveal fibrosis, present at the time of the 
treatment58 or existing over a long-term.60
Radiation maculopathy
Several treatments have been proposed for radiation macu-
lopathy, including laser photocoagulation, PDT, periocular 
injection of TA, IV anti-VEGF and, most recently, DEX 
implant (Table 6).63–68 All of these studies demonstrated a 
significant anatomical benefit with DEX implant in cases 
of recalcitrant radiation macular edema, with significant 
changes in visual acuity in most of the cases. Two com-
parative studies65,67 comparing DEX implant with anti-VEGF 
therapy, found no difference in outcomes, and a reduction in 
the number of injections in DEX-treated eyes.65
IOP increased in some eyes,63,64,66 all successfully treated 
by topical hypotonizing therapy. Cataract development 
in these cases64–66 could be caused by DEX or the radi-
ation therapy. 
Retinitis pigmentosa
The exact pathogenesis of macular edema, whether it is 
related to chronic and low-grade inflammatory process69 or 
to autoimmune process as antiretinal antibodies70 or to the 
failure of the retinal pigment epithelium pumping mecha-
nism, is unknown as yet.71 Treatments attempted include 
topical and systemic administration of CAI,71 NSAIDs, 
retinal laser photocoagulation, vitrectomy surgery,72 and IV 
anti-VEGF.73 Also, IV corticosteroids injections have been 
performed as these drugs may modulate the inflammatory 
mediators and the autoimmune process.74–76
The studies reporting on the use of DEX in macular 
edema related to retinitis pigmentosa consist of case report 
studies, which include only a few eyes (Table 7).77–80 Nev-
ertheless, an anatomical and functional improvement has 
been shown, but a relapse of macular edema occurred before 
6 months from the implant77 and an additional DEX was 
required in some cases.77,78 DEX implant proved to be safe 
with an IOP rise .21 mmHg recorded in only one eye.78





Previous treatment Treatment Follow-up Retreatment BCVA CMT Complications
Cebeci et al48 Case report 3 ivT Bev
Laser photocoagulation




NR 1 subcapsular 
cataract
Abbreviations: BCvA, best corrected visual acuity; Bev, bevacizumab; CMT, central macular thickness; DeX, dexamethasone implant; ivT, intravitreal; NR, not reported; 
PDT, photodynamic therapy.







Treatment Follow-up Retreatment BCVA CMT Complications
Sandali 
et al55
Case report 1 3 Bev ivT DeX 15 months 2 DeX From 20/32 to 
1 month: 20/20
From 398 µm 





Case report 1 3 Bev ivT
1 ivTA
DeX NR 3 DeX From 0.3 to 0.59 
logMAR: 6 weeks 
after 1st DeX; 
from 0.3 to 0.64 
logMAR: 6 weeks 
after 2nd DeX; 
from 0.3 to 0.78 
logMAR: 2 weeks 
after 3rd DeX
From 397 µm 
to 286 µm: 
6 weeks after 
1° DeX; 
6 weeks after 
2° DeX: 
279 µm;






Retrospective 1 8 ranibizumab 
ivT + laser 
DeX 17 months 4 DeX From 1 to 52 weeks: 
0.5 logMAR
From 607 µm 
to 52 weeks: 
346 µm
NR
Abbreviations: BCvA, best corrected visual acuity; Bev, bevacizumab; CMT, central macular thickness; DeX, dexamethasone implant; ivT, intravitreal; ivTA, intravitreal 
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DEX implant in macular edema 
after retinal surgery
DEX implant was used also in case of macular edema 
secondary to PPV for epiretinal membrane or macular hole 
or scleral buckling (Table 8).81–85 In all cases, an anatomical 
and functional improvement was shown, even though in 
2 cases, multiple DEX implants were performed because 
of recurrent macular edema.82 Additionally, the use of DEX 
allowed resolution of severe choroidal inflammation detected 
in 1 case following scleral buckle surgery.85
Conclusion
The use of DEX implant for all of the aforementioned 
macular pathologies merits consideration, and the results 
reported can support the use of DEX implant on a case-by-
case basis with the aim of improving patient outcomes in 
many macular pathologies.
In many of these cases, DEX implant allowed a reduc-
tion of CMT with an improvement of BCVA, even if, at 
long term, many eyes required retreatment because DEX 
implant started to lose its efficacy, sometimes at 3 months 
after the injection.
Many of these cases were refractory to previous treat-
ments, and DEX implant was administered as the last treat-
ment option. Consequently, the functional results provided 
may be influenced by the lateness of DEX implant use. 
Therefore, considering that many of the reported macular 
pathologies may be difficult to treat and that some of them 
are not especially uncommon, having an awareness of a new 
treatment option and its influence on the clinical course of the 
disease may represent a great assistance in clinical practice. 
Furthermore, the use of DEX remains the only solution in 
treating macular edema in vitrectomized eyes where the 
efficacy of other IV drug injections, such as anti-VEGF, is 
lost due to their pharmacokinetic properties.
DEX implant-related adverse events in this expanding-
use scenario are consistent with those previously docu-
mented for the DEX treatment of diabetic macular edema, 
uveitis, and retinal vein occlusion.10,86,87 In the cases that we 
analyzed, cataract was reported in up to 33% of the eyes after 
2 DEX implants,24 and the occurrence of ocular hyperten-
sion (IOP $25 mmHg) from 6%38 to 31%,32 all treated with 
topical therapy.
In conclusion, DEX implant may allow less frequent 
anti-VEGF treatment24,65 and therefore, the advantages for 
the patient are clear: the need to undergo stressful treat-
ment is removed while ocular and systemic adverse effects 
are reduced.
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